Leveraging synthetic biology technology and their adenovirus platform, Synbiotics is dedicated to creating a new generation of oncolytic virus products with enhanced tumor-killing capabilities. Founded by Professor Xie Zhen and his team from Tsinghua University, the company specializes in the development of novel drugs for the treatment of malignant tumors and genetic diseases. Through their expertise in synthetic biology, Synbiotics aims to enhance the effectiveness of cancer treatment by providing gene and cell drug development, scientific research, and clinical services.